Showing 1 - 18 results of 18 for search 'Renee N. Donahue', query time: 0.06s Refine Results
  1. 1
    Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade

    Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade by Yo-Ting Tsai, Jeffrey Schlom, Renee N. Donahue

    Published 2024-03-01
    Get full text
    Article
  2. 2
    Phosphoflow cytometry to assess cytokine signaling pathways in peripheral immune cells: potential for inferring immune cell function and treatment response in patients with solid tumors

    Phosphoflow cytometry to assess cytokine signaling pathways in peripheral immune cells: potential for inferring immune cell function and treatment response in patients with solid t... by Nicole J. Toney, Jeffrey Schlom, Renee N. Donahue

    Published 2023-09-01
    Get full text
    Article
  3. 3
    Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies

    Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies by Stephanie C. Pitts, Jeffrey Schlom, Renee N. Donahue

    Published 2024-05-01
    Get full text
    Article
  4. 4
    Peripheral immune biomarkers for immune checkpoint inhibition of solid tumours

    Peripheral immune biomarkers for immune checkpoint inhibition of solid tumours by Meghali Goswami, Nicole J. Toney, Stephanie C. Pitts, Carolina Celades, Jeffrey Schlom, Renee N. Donahue

    Published 2024-08-01
    Get full text
    Article
  5. 5
    Early changes in immune cell subsets with corticosteroids in patients with solid tumors: implications for COVID-19 management

    Early changes in immune cell subsets with corticosteroids in patients with solid tumors: implications for COVID-19 management by Renee N Donahue, Jeffrey Schlom, James L Gulley, Lisa Cordes, Jennifer L Marté, Nicole J Toney

    Published 2020-10-01
    Get full text
    Article
  6. 6
    Hypothesis: the generation of T cells directed against neoepitopes employing immune-mediating agents other than neoepitope vaccines

    Hypothesis: the generation of T cells directed against neoepitopes employing immune-mediating agents other than neoepitope vaccines by Renee N Donahue, Jeffrey Schlom, James L Gulley, James W Hodge, Claudia Palena, Duane H Hamilton, Sofia R Gameiro

    Published 2024-07-01
    Get full text
    Article
  7. 7
    1063 Immune correlates with response in patients with metastatic solid tumors treated with a tumor targeting immunocytokine NHS-IL12

    1063 Immune correlates with response in patients with metastatic solid tumors treated with a tumor targeting immunocytokine NHS-IL12 by Renee N Donahue, Jeffrey Schlom, James L Gulley, Julius Strauss, Margaret E Gatti-Mays, Nicole J Toney, Nicholas P Tschernia, Stephanie C Pitts

    Published 2023-11-01
    Article
  8. 8
    Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients not Detected in Analysis of Standard Immune Cell Types

    Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients not Detected in Analysis of Standard Immune Cell... by Lauren M. Lepone, Renee N. Donahue, Italia Grenga, Simon Metenou, Jacob Richards, Christopher R. Heery, Ravi A. Madan, James L. Gulley, Jeffrey Schlom

    Published 2016-03-01
    Get full text
    Article
  9. 9
    PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations

    PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations by Jeffrey Schlom, James W Hodge, Clint T. Allen, Shahrooz Rabizadeh, Patrick Soon-Shiong, John H. Lee, Renee N. Donahue, Kristen Solocinski, Michelle R Padget, Kellsye P Fabian, Yvette Robbins

    Published 2020-05-01
    Get full text
    Article
  10. 10
    1413 Immunogenicity of SARS-CoV-2 mRNA vaccines in individuals with thymic epithelial tumors

    1413 Immunogenicity of SARS-CoV-2 mRNA vaccines in individuals with thymic epithelial tumors by Arun Rajan, Renee N Donahue, Jeffrey Schlom, James L Gulley, Chen Zhao, Roa Harb, Seth M Steinberg, Eva Szabo, Shannon Swift, Meredith McAdams, Madison Ballman, Hanna S Loving, Hyoyoung Choo-Wosoba

    Published 2023-11-01
    Article
  11. 11
    781 A phase II, open-label trial of bintrafusp alfa (M7824) in subjects with thymoma and thymic carcinoma (trial in progress)

    781 A phase II, open-label trial of bintrafusp alfa (M7824) in subjects with thymoma and thymic carcinoma (trial in progress) by Arun Rajan, Renee N Donahue, Jeffrey Schlom, James L Gulley, Chen Zhao, Nirmal Choradia, Seth M Steinberg, Yo-Ting Tsai, Eva Szabo, Shannon Swift, Christine Feierabend, Meredith McAdams, Carolina Celades, Molly Bingham, Susan Sansone, Meenakshi Shelat

    Published 2023-11-01
    Article
  12. 12
    Systemic immune changes accompany combination treatment with immunotoxin LMB‐100 and nab‐paclitaxel

    Systemic immune changes accompany combination treatment with immunotoxin LMB‐100 and nab‐paclitaxel by Guillaume Joe Pegna, Min‐Jung Lee, Cody J. Peer, Mehwish I. Ahmad, David J. Venzon, Yunkai Yu, Akira Yuno, Seth M. Steinberg, Liang Cao, William D. Figg, Renee N. Donahue, Raffit Hassan, Ira Pastan, Jane B. Trepel, Christine Alewine

    Published 2023-02-01
    Get full text
    Article
  13. 13
    Efficacy, safety, and biomarker analyses of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with advanced non-small cell lung cancer

    Efficacy, safety, and biomarker analyses of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with advanced non-small cell lung cancer by Arun Rajan, Renee N Donahue, Jeffrey Schlom, James L Gulley, Elizabeth Lamping, Osama Rahma, Houssein Abdul Sater, Jennifer L Marté, Beatriz Walter-Rodriguez, Yulia Vugmeyster, Yo-Ting Tsai, Shania Bailey, Wiem Lassoued, Richy Agajanian, Andrew Weisman, Rena Ito, Masashi Sato, Andreas Machl

    Published 2024-03-01
    Get full text
    Article
  14. 14
    First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma

    First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma by Renee N Donahue, Jeffrey Schlom, James L Gulley, Mario Sznol, Andreas Schroeder, Julius Strauss, Luc Dirix, Michele Maio, Frank Beier, Alain Ravaud, Jean-Laurent Deville, Marco Maruzzo, XiaoZhe Wang, Yulia Vugmeyster, Sarah Chennoufi, Yo-Ting Tsai, Russell K Pachynski, Theodore S Gourdin, Joerg Seebeck

    Published 2023-05-01
    Get full text
    Article
  15. 15
    Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer

    Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer by Renee N Donahue, Jeffrey Schlom, James L Gulley, Christopher R Heery, Ravi A Madan, Marijo Bilusic, Fatima Karzai, Houssein Abdul Sater, Jennifer L Marté, Beatriz Walter-Rodriguez, Seth M Steinberg, Guinevere Chun, Stephanie A Harmon, Ismail Baris Turkbey, Peter L Choyke, William L Dahut, Peter A Pinto

    Published 2020-05-01
    Get full text
    Article
  16. 16
    Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies

    Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies by Renee N Donahue, Jeffrey Schlom, James L Gulley, Ravi A Madan, Caroline Jochems, Elizabeth Lamping, Julius Strauss, Marijo Bilusic, Fatima Karzai, Christian S Hinrichs, Edward McClay, Jennifer L Marté, Lisa M Cordes, Andrew Hill, Byoung Chul Cho, Sébastien Salas, Laureen S Ojalvo, P Alexander Rolfe, Margaret E Gatti-Mays, Jason M Redman, Houssein A Sater, Andrea Burmeister, Genevieve Jehl

    Published 2020-10-01
    Get full text
    Article
  17. 17
    Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study

    Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study by Filipa Lynce, Candace Mainor, Renee N. Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J. Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher Gallagher, Rita Nanda, Deena Graham, Erica M. Stringer-Reasor, Neelima Denduluri, Julie Collins, Ami Chitalia, Shruti Tiwari, Raquel Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M. Tolaney, Sandra M. Swain, Paula Pohlmann, Heather A. Parsons, Claudine Isaacs

    Published 2024-03-01
    Get full text
    Article
  18. 18
    Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study

    Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study by Filipa Lynce, Candace Mainor, Renee N. Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J. Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher Gallagher, Rita Nanda, Deena Graham, Erica M. Stringer-Reasor, Neelima Denduluri, Julie Collins, Ami Chitalia, Shruti Tiwari, Raquel Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M. Tolaney, Sandra M. Swain, Paula Pohlmann, Heather A. Parsons, Claudine Isaacs

    Published 2024-05-01
    Get full text
    Article

Search Tools: